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remarkably high in a no fault jurisdiction and strongly
predictive of such occurences.
Doctors in many countries are discouraged from
reporting medical errors,4 yet litigation in tort jurisdic›
tions is becoming more common.5 In no fault
jurisictions, the relatively high level of annotation in
patient records that we found could provide a basis for
more vigorous error reporting.
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Review of deaths related to taking ecstasy, England and
Wales, 1997›2000
Fabrizio Schifano, Adenekan Oyefeso, Lucy Webb, Mike Pollard, John Corkery, A Hamid Ghodse
The lack of data about the lethal consequences of taking
ecstasy has led to high profile reports of deaths in the
media and also the idea that ecstasy is safe. The United
Kingdom accounts for most of the ecstasy tablets—
normally containing methylenedioxymethampheta›
mine (MDMA) or 3,4›methylenedioxyamphetamine
(MDA)—seized in the European Union.1 The rate of
deaths related to taking ecstasy in people aged 15›24
during 1995 and 1996 in England was 18 and between
1995 and 1997 in Scotland was 11.2 The risk of using
ecstasy varies between one death in 2000 first time users
to one death in 50 000 first time users.2
The National Programme on Substance Abuse
Deaths was established after the Home Office Addicts
Index closed. We report all the information recorded
in the programme’s database between 1 July 1997 and
30 June 2000 about deaths in England and Wales
related to taking ecstasy.3
Participants, methods, and results
Deaths are included on the database of the National
Programme on Substance Abuse Deaths if one or more
psychoactive substances are directly implicated in death,
if the patient had a history of dependence on or misuse
of psychoactive drugs, or if controlled drugs are found
during necropsy. The response rate from coroners in
England and Wales was high (about 95%).3 We defined
deaths related to ecstasy as a coroner’s report including
the text “ecstasy,” “XTC,” “MDMA,” or “MDA.”3
We identified 81 deaths related to taking ecstasy.
Results of toxicological examination were made
available in 75 cases; MDMA accounted for 68 (91%),
MDA for 7 (9%), and opiates or opioids for 44 (59%) of
these cases. In 26 (38%) cases, one or more drugs
(mostly hypnotics or sedatives) had been prescribed to
the deceased patient (table).
Comment
Most people who died from taking ecstasy were white
employed men in their late 20s, known to services as
Characteristics of 81 people whose death was related to ecstasy
in England and Wales between 1 July 1997 and 30 June 2000.
Values are numbers (percentages) unless stated otherwise
Characteristic Value
Sex:
Male 66 (81)
Female 15 (19)
Age (years) 27.2 (range 16›50)
Ethnic origin:
White 71 (88)
Black African 3 (4)
Other 7 (9)
Employment status:
Employed 37 (46)
Unemployed 36 (44)
Student 8 (10)
Patients known as drug addicts to services or primary care 46 (57)
Most common causes of death recorded by coroners:
Polysubstance poisoning 50 (62)
Only MDMA poisoning 6 (7)
Others* 25 (31)
Place of death:
Private residence 40 (49)
Hospital 25 (31)
Pub or club 2 (2)
Other 14 (17)
Area of death:
London 16 (20)
Southeast England 10 (12)
Northeast England 11 (14)
Northwest England 14 (17)
Central England 11 (14)
Other 19 (23)
Month of death:
January 10 (12)
July 10 (12)
August 8 (10)
Other 53 (65)
Day of death:
Saturday 16 (20)
Sunday 29 (36)
Other 36 (44)
*For example heart attack, trauma, drowning, or hyperpyrexia.
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drug addicts, and died at home. Typically, the deceased
took several different (prescribed and non›prescribed)
drugs with ecstasy; the large number of people who
also took opiates seems surprising but confirms previ›
ous findings and may explain why a high proportion of
the victims were known to services.4 People may have
taken ecstasy with other drugs to modulate the
effects—ecstasy had, at least, a facilitating role in
causing death. A small proportion of people (6/81;
7%) died after taking only ecstasy—a previously
doubted possibility.5 Toxicological tests could detect all
drugs that had been taken in the 2›3 days before death
and gave only limited information about which drugs
had been taken on the last occasion. Deaths related to
ecstasy occurred in two clusters (urban industrial areas
in southeast and northern England); people died
mostly at party times (weekends, summer, and at New
Year).
Information about the incidence of taking ecstasy
and other drugs and amounts taken is unfortunately
lacking; the database of the National Programme on
Substance Abuse Deaths (which is being extended to
Northern Ireland and Scotland) will collect more
information in future—for example, the concentration
of individual drugs in tissues—to obtain a better under›
standing of the role of other drugs in deaths related to
taking ecstasy.
Contributors: FS wrote the manuscript and coordinated the
study. AO, LW, MP, and JC collected data and interpreted the
results. AHG participated in interpreting the results. FS is
guarantor.
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Recent changes in lung cancer incidence for south Asians:
a population based register study
Lucy K Smith, Michael D Peake, Johannes L Botha
In Britain the incidence of lung cancer among south
Asians (Indian, Pakistani, and Bangladeshi) is much
lower than in the rest of the population.1 In the UK
south Asian population, however, it is the commonest
cancer for men and the second commonest for
women.2 Little has been reported on lung cancer
trends among south Asians in Britain. We explored
trends in lung cancer incidence from 1990 to 1999 in
Leicester (22% of residents classified as south Asian in
1991 census).
Participants, methods, and results
We identified cases of lung cancer diagnosed in Leices›
ter residents between 1 January 1990 and 31
December 1999 from the Trent Cancer Registry.
Ethnicity data were not available for all patients, so we
used software assessing forename and surname to clas›
sify patients as south Asian or non›south Asian,3 with
visual inspection of the data to increase accuracy. We
assessed deprivation using the Townsend index. The
local research ethics committee approved the study.
Population estimates at the level of electoral wards
from the 1991 census (categorised by sex, ethnicity, and
5 year age bands) were aggregated by deprivation ter›
tile to calculate lung cancer incidence. We investigated
variation in incidence by ethnicity, deprivation, age,
and year of diagnosis and any interactions between
them using Poisson regression separately for men and
women. We calculated the interaction between period
of diagnosis (1990›4 or 1995›9) and ethnicity to com›
pare trends over time.
Of the 1902 patients with lung cancer identified, 76
were classified as south Asian (4%). South Asians were
slightly younger than non›south Asians (median age
70.3 v 72.1 years). After adjusting for differences in age
and deprivation, we found lung cancer rates were lower
for south Asians than non›south Asians (incidence
ratio for men 0.41 (95% confidence interval 0.31 to
0.54), for women 0.32 (0.20 to 0.50)).
The adjusted incidence increased over time for
south Asian men but decreased for non›south Asian
men (P=0.038), with an increase in risk of 43% for
south Asian men (incidence ratio for 1990›4 v 1995›9
1.43 (0.84 to 2.44)) and a decrease of 19% for
non›south Asian men (0.81 (0.72 to 0.91)). For
non›south Asian men, the decrease in incidence
occurred in those from more deprived areas, where
lung cancer incidence was higher (see figure). There
was no evidence of a trend with deprivation over time
for south Asian men.
Patterns for women were different, with slight
increases in lung cancer incidence over time for both
south Asians and non›south Asians and no evidence of
differing patterns over time (P=0.489). South Asian
women had a 50% increase in risk (1.50 (0.61 to 3.67)),
while the increase in risk for non›south Asians was 9%
(1.09 (0.93 to 1.28)). The changes in incidence over
time were similar for all levels of deprivation (see
figure).
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